PN-101

Paean Biotechnology Inc. · Phase 2 active Biologic

PN-101 is an allogeneic mitochondria therapy being developed by Paean Biotechnology Inc. for refractory polymyositis and dermatomyositis. It has completed a Phase 1/2 trial and is currently recruiting for a Phase 2 trial. The therapy aims to improve mitochondrial function and reduce inflammation in muscle tissues.

At a glance

Generic name	PN-101
Sponsor	Paean Biotechnology Inc.
Modality	Biologic
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PN-101 CI brief — competitive landscape report
PN-101 updates RSS · CI watch RSS
Paean Biotechnology Inc. portfolio CI